Stock analysis searches answered, part 15 of 43

Tsun yip holdings limited bullish and bearish analyst opinions

Read from its name, “Tsun yip holdings limited” is a a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada) entity — “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. Its accounts and exchange notices are published through that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Tsun yip holdings limited bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Tsun yip holdings limited”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “tsun” (search terms considered: tsun, yip).

Even the shorter phrase “Tsun yip holdings” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (tsun, yip) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 7 entities whose registered name contains the word “tsun”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “tsun” 7, “yip” 44. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “tsun”: CHAN EDWIN TSUN KAY (CIK 1674422), CHEN EDWARD TSUN-WEI (CIK 2026669), KAO TSUN-MING (CIK 2022598); containing “yip”: CHI YIP SIN (CIK 1737085), CHONG YIP LOONG (CIK 2122612), HO HIN YIP (CIK 2119194). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “tsun” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Txt e-solutions s.p.a. bullish and bearish analyst opinions

“S.p.A.” is the Italian joint-stock company form (società per azioni). The name “Txt e-solutions s.p.a.” therefore points to a company organised in Italy, and its official disclosures are on Borsa Italiana and CONSOB’s issuer disclosures (www.consob.it), not on EDGAR.

No SEC filer could be matched to “Txt e-solutions s.p.a. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Txt e-solutions s.p.a.” appears in 379+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “txt” (search terms considered: txt, e-solutions).

In the 100 most relevant full-text hits returned for “Txt e-solutions s.p.a.”, filings range from 2011-05-23 to 2026-09-24. The filers whose documents mention it most often are Dimensional ETF Trust (CIK 0001816125) (37 hits); John Hancock Funds II (CIK 0001331971) (21 hits); Brighthouse Funds Trust II (CIK 0000710826) (11 hits); KIT digital, Inc. (CIK 0001076700) (6 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 4 entities whose registered name contains the word “txt”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “txt” 4, “e-solutions” 0. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “txt” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Ucloudlink group inc. bullish and bearish analyst opinions

This section ties “Ucloudlink group inc. bullish and bearish analyst opinions” to uCloudlink Group Inc. (ticker UCL), SEC Central Index Key 1775898, an EDGAR registrant classified as “Communications Services, NEC” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-10-13, and this view starts from filings dated on or before 2026-06-08. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-03-27 by uCloudlink Group Inc. (CIK 1775898) (passage 2, continuing from the earlier excerpt) — source document:

In January 2015, we established Beijing uCloudlink Technology Co., Ltd., through which we gained control over Shenzhen uCloudlink Network Technology Co., Ltd. and Beijing uCloudlink New Technology Co., Ltd. by entering into a series of contractual arrangements with Shenzhen uCloudlink Network Technology Co., Ltd. and Beijing uCloudlink New Technology Co., Ltd. and their respective shareholders. In addition, we conduct our business through the following entities: primarily for marketing and sales: ● UCLOUDLINK (UK) CO. LTD in the UK in October 2014; ● Ucloudlink (America), Ltd. in the United States in August 2016; ● UCLOUDLINK (SINGAPORE) PTE. LTD. in Singapore in May 2017; 60 ● UCLOUDLINK SDN. BHD. in Malaysia in August 2017; ● uCloudlink Japan Co., Ltd. in Japan in March 2018; ● UCLOUDLINK UK LIMITED in the UK in February 2021; primarily for technology research and development: ● Shenzhen Ucloudlink Technology Limited in mainland China in July 2015; and primarily for hardware exportation: ● Shenzhen uCloudlink Co., Ltd. in mainland China in June 2018; ● UCLOUDLINK (VIETNAM) COMPANY LIMITED in Vietnam in March 2025; ● UCLOUDLINK (IRELAND) LIMITED in Ireland in September 2025; ● PetAIVerse Holding Inc.

Financial trend for uCloudlink Group Inc. from annual reports, periods 2018-12-31 to 2021-12-31: revenue was tagged only for 2021-12-31 at $73.82 million; net income (loss) went from -$26.56 million (2018-12-31) to -$46.04 million (2021-12-31), a change of -73.4%; total assets went from $90.10 million (2019-12-31) to $67.12 million (2021-12-31), a change of -25.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1775898, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures uCloudlink Group Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on uCloudlink Group Inc. (CIK 1775898) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 60 8-K or 6-K reports in uCloudlink Group Inc.’s recent EDGAR index, the 4 listed here run from 2025-10-17 to 2026-03-18, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1775898 is on the EDGAR company page; the latest 20-F there is dated 2026-03-27 and the oldest filing in the recent index dates from 2019-05-24. One example from this record is the 4 filed 2026-09-01 (document). Insider trades for uCloudlink Group Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ultralife corporation bullish and bearish analyst opinions

This section ties “Ultralife corporation bullish and bearish analyst opinions” to ULTRALIFE CORP (ticker ULBI), SEC Central Index Key 875657, an EDGAR registrant classified as “Miscellaneous Electrical Machinery, Equipment & Supplies” and organised in DE, formerly known as ULTRALIFE BATTERIES INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-08-07. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-23 by ULTRALIFE CORP (CIK 875657) — source document:

We offer products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government, defense and commercial sectors. With an emphasis on strong engineering and a collaborative approach to problem solving, we design and manufacture power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom engineered systems related to those product lines. We continually evaluate ways to grow, including the design, development and sale of new products, expansion of our sales force to penetrate new markets and territories, as well as seeking opportunities to expand through acquisitions. We sell our products worldwide through a variety of trade channels, including original equipment manufacturers (“OEMs”), industrial and defense supply distributors, and directly to U.S. and foreign defense departments.

Financial trend for ULTRALIFE CORP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $131.84 million (2022-12-31) to $191.16 million (2025-12-31), a change of +45.0%; net income (loss) went from -$119,000 (2022-12-31) to -$5.90 million (2025-12-31), a change of -4856.3%; total assets went from $168.43 million (2022-12-31) to $216.91 million (2025-12-31), a change of +28.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 875657, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures ULTRALIFE CORP did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ULTRALIFE CORP (CIK 875657) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-07, and the most recent 10-K annual report was filed 2026-03-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 218 8-K or 6-K reports in ULTRALIFE CORP’s recent EDGAR index, the 4 listed here run from 2026-03-10 to 2026-08-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 875657 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-29 and the oldest filing in the recent index dates from 2006-09-28. Insider trades for ULTRALIFE CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Uy scuti acquisition corp. bullish and bearish analyst opinions

This section ties “Uy scuti acquisition corp. bullish and bearish analyst opinions” to UY Scuti Acquisition Corp. (ticker UYSC, UYSCR, UYSCU), SEC Central Index Key 2036973, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 425 dated 2026-10-23, and this view starts from filings dated on or before 2026-03-27. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-07-14 by UY Scuti Acquisition Corp. (CIK 2036973) (passage 3, continuing from the earlier excerpt) — source document:

Due to a reduction in the offering size, we subsequently entered into an amended securities subscription agreement with our sponsor pursuant to which 287,500 Founder Shares were cancelled such that our sponsor now owns an aggregate of 1,437,500 Founder Shares, of which, up to 187,500 shares were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option is exercised. As the over-allotment option was exercised in full, none of the Founder Shares were forfeited. In three closings on April 1, 2025, April 7, 2025, and April 9, 2025, the Company sold an aggregate 5,750,000 Units at a price of $10.00 per Unit for a total of $57,500,000 (including 750,000 Units from the exercise of the underwriters’ over-allotment option) (the “Units”).

Financial trend for UY Scuti Acquisition Corp. from quarterly and annual reports (three-month periods), periods 2024-09-30 to 2025-06-30: net income (loss) went from -$49,836 (2024-09-30) to $332,078 (2025-06-30), a change of +766.3%; total assets was tagged only for 2025-06-30 at $58.68 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2036973, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures UY Scuti Acquisition Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on UY Scuti Acquisition Corp. (CIK 2036973) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-07-14. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 17 8-K or 6-K reports in UY Scuti Acquisition Corp.’s recent EDGAR index, the 4 listed here run from 2025-07-24 to 2026-03-27, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2036973 is on the EDGAR company page; the latest 10-K there is dated 2026-07-14 and the oldest filing in the recent index dates from 2024-09-30. One example from this record is the 10-Q filed 2026-08-13 (document). Insider trades for UY Scuti Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Verrica pharmaceuticals inc. bullish and bearish analyst opinions

This section ties “Verrica pharmaceuticals inc. bullish and bearish analyst opinions” to Verrica Pharmaceuticals Inc. (ticker VRCA), SEC Central Index Key 1660334, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-08-18. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-11 by Verrica Pharmaceuticals Inc. (CIK 1660334) — source document:

We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Our commercial product, YCANTH (VP-102), was approved by the U.S. Food and Drug Administration, or FDA, in July 2023 for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Financial trend for Verrica Pharmaceuticals Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $7.57 million (2024-12-31) to $35.58 million (2025-12-31), a change of +370.2%; net income (loss) went from -$24.49 million (2022-12-31) to -$17.89 million (2025-12-31), a change of +27.0%; total assets went from $44.72 million (2022-12-31) to $47.13 million (2025-12-31), a change of +5.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1660334, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Verrica Pharmaceuticals Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Verrica Pharmaceuticals Inc. (CIK 1660334) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-11. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 110 8-K or 6-K reports in Verrica Pharmaceuticals Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-11 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1660334 is on the EDGAR company page; the latest 10-K there is dated 2026-03-11 and the oldest filing in the recent index dates from 2015-12-17. Insider trades for Verrica Pharmaceuticals Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Vfsww october 2026 earnings expectations

This section ties “Vfsww october 2026 earnings expectations” to VinFast Auto Ltd. (ticker VFS, VFSWW), SEC Central Index Key 1913510, an EDGAR registrant classified as “Motor Vehicles & Passenger Car Bodies” and organised in Singapore, formerly known as VinFast Auto Pte. Ltd. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-19. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-04-30 by VinFast Auto Ltd. (CIK 1913510) — source document:

Ltd., a private limited company (Company Registration No. 201501874G) under the Companies Act 1967 of Singapore (the “Singapore Companies Act”). We commenced operations in June 2017 in Hanoi, Vietnam through VinFast Vietnam. In May 2018, VinFast Vietnam changed its name to “VinFast Trading and Production Limited Liability Company” and our head office was relocated to Hai Phong, Vietnam. The construction of our electric scooter manufacturing plant was completed in April 2018 and we started production of our first electric scooter model, branded Klara, in November 2018. We broke ground on our automobile manufacturing plant in September 2017 and officially launched the plant in June 2019. In December 2021, VinFast Vietnam was converted into a joint stock company under the name, “VinFast Trading and Production Joint Stock Company.” Our Company’s name was changed to “VinFast Trading & Investment Pte.

Financial trend for VinFast Auto Ltd. from annual reports, periods 2023-12-31 to 2024-12-31: revenue went from $1.17 billion (2023-12-31) to $1.81 billion (2024-12-31), a change of +54.7%; net income (loss) went from -$2.40 billion (2023-12-31) to -$3.18 billion (2024-12-31), a change of -32.1%; total assets went from $5.52 billion (2023-12-31) to $6.41 billion (2024-12-31), a change of +16.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1913510, tags Assets, NetIncomeLoss, Revenues; 2 periods shown, dashes mark figures VinFast Auto Ltd. did not tag for that period.

For reported results, VinFast Auto Ltd.’s (CIK 1913510) EDGAR record shows no 10-Q in the recent window and its latest annual report (20-F) 2026-04-30.

Current reports. Of the 84 8-K or 6-K reports in VinFast Auto Ltd.’s recent EDGAR index, the 4 listed here run from 2026-09-16 to 2026-10-19, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1913510 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2022-03-31. Insider trades for VinFast Auto Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Virco mfg. corporation bullish and bearish analyst opinions

This section ties “Virco mfg. corporation bullish and bearish analyst opinions” to VIRCO MFG CORPORATION (ticker VIRC), SEC Central Index Key 751365, an EDGAR registrant classified as “Public Bldg & Related Furniture” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-15. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-04-08 by VIRCO MFG CORPORATION (CIK 751365) — source document:

Designing, producing, and distributing high-value furniture for a diverse family of customers is a 76-year tradition at Virco Mfg. Corporation (“Virco” or the “Company”, or in the first person, “we”, “us” or “our”). Virco was incorporated in California in February 1950 and reincorporated in Delaware in April 1984. Virco started as a local manufacturer of chairs and desks for Los Angeles area schools, and over the years has become the largest manufacturer and supplier of movable educational furniture and equipment for the preschool through 12th grade market in the United States. As the market for school furniture has evolved, the Company has developed significant selling and service capabilities. The Company employs interior designers, CAD layout specialists, and project management specialists to support its direct sales force.

Financial trend for VIRCO MFG CORPORATION from annual reports, periods 2023-01-31 to 2026-01-31: revenue went from $231.06 million (2023-01-31) to $199.65 million (2026-01-31), a change of -13.6%; net income (loss) went from $16.55 million (2023-01-31) to $2.57 million (2026-01-31), a change of -84.5%; total assets went from $150.13 million (2023-01-31) to $174.18 million (2026-01-31), a change of +16.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 751365, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures VIRCO MFG CORPORATION did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on VIRCO MFG CORPORATION (CIK 751365) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-04, and the most recent 10-K annual report was filed 2026-04-08. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 176 8-K or 6-K reports in VIRCO MFG CORPORATION’s recent EDGAR index, the 4 listed here run from 2026-04-08 to 2026-09-04, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 751365 is on the EDGAR company page; the latest 10-K there is dated 2026-04-08 and the oldest filing in the recent index dates from 1995-06-13. Insider trades for VIRCO MFG CORPORATION appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Virtra, inc. bullish and bearish analyst opinions

This section ties “Virtra, inc. bullish and bearish analyst opinions” to VirTra, Inc (ticker VTSI), SEC Central Index Key 1085243, an EDGAR registrant classified as “Miscellaneous Manufacturing Industries” and organised in NV, formerly known as VIRTRA SYSTEMS INC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-09-15, and this view starts from filings dated on or before 2026-05-29. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-26 by VirTra, Inc (CIK 1085243) (passage 2, continuing from the earlier excerpt) — source document:

Our Articles of Incorporation filed in Nevada authorize us to issue 62,500,000 shares, of which (1) 60,000,000 shares shall be common stock, par value $0.0001 per share (the “Common Stock”), of which (a) 50,000,000 shares shall be Common Stock, (b) 2,500,000 shares shall be Class A Common Stock, par value $0.0001 per share (the “Class A Common Stock”), and (c) 7,500,000 shares shall be Class B Common Stock, par value $0.0001 per share (the “Class B Common Stock”) and (2) 2,500,000 shares shall be Preferred Stock, par value $0.0001 per share, which may, at the sole discretion of the Board of Directors, be issued in one or more series (the “Preferred Stock”).

Financial trend for VirTra, Inc from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $93,594 (2026-03-31) to $5.76 million (2026-06-30), a change of +6057.8%; net income (loss) went from -$388,567 (2025-09-30) to -$261,258 (2026-06-30), a change of +32.8%; total assets went from $66.20 million (2025-09-30) to $66.18 million (2026-06-30), a change of -0.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1085243, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures VirTra, Inc did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on VirTra, Inc (CIK 1085243) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 115 8-K or 6-K reports in VirTra, Inc’s recent EDGAR index, the 4 listed here run from 2025-08-11 to 2026-02-17, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1085243 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 1999-12-06. One example from this record is the 10-Q filed 2026-08-13 (document). Insider trades for VirTra, Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Vivopower plc bullish and bearish analyst opinions

This section ties “Vivopower plc bullish and bearish analyst opinions” to VivoPower PLC (ticker VIVO), SEC Central Index Key 1681348, an EDGAR registrant classified as “Electric & Other Services Combined” and organised in United Kingdom, formerly known as VivoPower International PLC. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-08-28. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2025-10-30 by VivoPower PLC (CIK 1681348) — source document:

Operating and Financial Review and Prospects 30 A. Operating Results 30 B. Liquidity and Capital Resources 39 C. Research and Development, Patents, Licenses, etc. 45 D. Trend Information 46 E. Critical Accounting Estimates 46 Item 6. Directors, Senior Management and Employees 47 A. Directors and Senior Management 47 B. Board Diversity 50 C. Compensation 50 D. Board Practices 52 E. Employees 55 F. Share Ownership 56 G. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation 57 Item 7. Major Shareholders and Related Party Transactions 57 A. Major Shareholders 57 B. Related Party Transactions 58 C. Interests of Experts and Counsel 60 Item 8. Financial Information 60 A. Consolidated Statements and Other Financial Information 60 B. Significant Changes 61 Item 9.

Financial trend for VivoPower PLC from annual reports, periods 2022-06-30 to 2025-06-30: revenue went from $10.16 million (2022-06-30) to $61,000 (2025-06-30), a change of -99.4%; net income (loss) went from -$22.05 million (2022-06-30) to -$12.79 million (2025-06-30), a change of +42.0%; total assets went from $69.66 million (2022-06-30) to $97.13 million (2025-06-30), a change of +39.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1681348, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures VivoPower PLC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on VivoPower PLC (CIK 1681348) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2025-10-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 247 8-K or 6-K reports in VivoPower PLC’s recent EDGAR index, the 4 listed here run from 2026-07-29 to 2026-08-28, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1681348 is on the EDGAR company page; the latest 20-F there is dated 2025-10-30 and the oldest filing in the recent index dates from 2016-08-11. Insider trades for VivoPower PLC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Wabash national corporation bullish and bearish analyst opinions

This section ties “Wabash national corporation bullish and bearish analyst opinions” to WABASH NATIONAL Corp (ticker WNC), SEC Central Index Key 879526, an EDGAR registrant classified as “Truck Trailers” and organised in DE, formerly known as WABASH NATIONAL CORP /DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-24, and this view starts from filings dated on or before 2026-07-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-18 by WABASH NATIONAL Corp (CIK 879526) (passage 2, continuing from the earlier excerpt) — source document:

In addition, through Wabash Hub, customers gain access to a nationwide parts and service network, Trailers as a Service (TaaS)℠, and advanced tools designed to streamline operations and drive growth. We have achieved this diversification through acquisitions, organic growth, and product innovation. We believe our position as a leader in our key industries is the result of longstanding relationships with our core customers, our demonstrated ability to attract new customers, our broad and innovative product lines, our engineering leadership, and our extensive dealer and preferred partner network. More importantly, we believe our leadership position is indicative of the Values and Leadership Principles that guide our actions. At Wabash, it is our focus on people, purpose, and performance that drives us to do better.

Financial trend for WABASH NATIONAL Corp from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-03-31: net income (loss) went from -$9.59 million (2025-06-30) to -$45.17 million (2026-03-31), a change of -371.1%; total assets went from $1.38 billion (2025-06-30) to $1.23 billion (2026-03-31), a change of -10.7%. Values are as filed and not adjusted for restatements, splits or currency.

Analyst ratings, price targets and “bullish” or “bearish” calls on WABASH NATIONAL Corp (CIK 879526) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-29, and the most recent 10-K annual report was filed 2026-02-18. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 242 8-K or 6-K reports in WABASH NATIONAL Corp’s recent EDGAR index, the 4 listed here run from 2026-05-01 to 2026-07-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 879526 is on the EDGAR company page; the latest 10-K there is dated 2026-02-18 and the oldest filing in the recent index dates from 2010-05-14. One example from this record is the 8-K filed 2026-08-13 (document). Insider trades for WABASH NATIONAL Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Wallbox n.v. bullish and bearish analyst opinions

This section ties “Wallbox n.v. bullish and bearish analyst opinions” to Wallbox N.V. (ticker WBX), SEC Central Index Key 1866501, an EDGAR registrant classified as “Miscellaneous Electrical Machinery, Equipment & Supplies” and organised in Netherlands, formerly known as Wallbox B.V.. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a F-1/A dated 2026-10-22. Nothing here is a recommendation to trade the security.

Financial trend for Wallbox N.V. from annual reports, periods 2021-12-31 to 2024-12-31: revenue went from 71,579,000 EUR (2021-12-31) to 163,943,000 EUR (2024-12-31), a change of +129.0%; net income (loss) went from -223,777,000 EUR (2021-12-31) to -151,792,000 EUR (2024-12-31), a change of +32.2%; total assets went from 342,613,000 EUR (2021-12-31) to 353,066,000 EUR (2024-12-31), a change of +3.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1866501, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Wallbox N.V. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Wallbox N.V. (CIK 1866501) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-09. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 76 8-K or 6-K reports in Wallbox N.V.’s recent EDGAR index, the 4 listed here run from 2026-07-02 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 247 recent EDGAR filings, Wallbox N.V. most often filed 6-K (76), 425 (27), 144 (21), 424B3 (15). A selection from 2026-07-13 to 2026-10-22:

The full record for CIK 1866501 is on the EDGAR company page; the latest 20-F there is dated 2026-04-09 and the oldest filing in the recent index dates from 2021-06-09. Insider trades for Wallbox N.V. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Xsolla spac 1 bullish and bearish analyst opinions

This section ties “Xsolla spac 1 bullish and bearish analyst opinions” to Xsolla SPAC 1 (ticker XSLL, XSLLU, XSLLW), SEC Central Index Key 2088807, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-14, and this view starts from filings dated on or before 2026-03-03. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-31 by Xsolla SPAC 1 (CIK 2088807) (passage 2, continuing from the earlier excerpt) — source document:

We believe we have a deep and broad network of relationships and sector expertise to source and evaluate potential transactions, enhancing our ability to position us as a partner of choice with potential target companies. The extensive investing track record and operational experience of the management team, including significant public company executive and board experience are expected to enhance our credibility with prospective investors, and will allow us to be a value-added partner to the management team and stakeholders following an initial business combination. We believe our extensive M&A and capital markets experience will enable us to successfully execute an initial business combination transaction. We may pursue an initial business combination in any business or industry but intend to focus our search on a target business in an industry where we believe the expertise of our management team will provide us with a competitive advantage in completing a successful initial business combination.

Financial trend for Xsolla SPAC 1 from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from $1.10 million (2026-03-31) to $1.66 million (2026-06-30), a change of +50.1%; total assets went from $207.17 million (2026-03-31) to $209.00 million (2026-06-30), a change of +0.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2088807, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Xsolla SPAC 1 did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Xsolla SPAC 1 (CIK 2088807) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Xsolla SPAC 1 — registration statements, prospectuses and merger proxies — are filed on EDGAR; 5 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-01-29.

Current reports. Of the 5 8-K or 6-K reports in Xsolla SPAC 1’s recent EDGAR index, the 1 listed here run from 2026-02-02 to 2026-02-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2088807 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2025-10-09. One example from this record is the SCHEDULE 13G filed 2026-05-13 (document). Insider trades for Xsolla SPAC 1 appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Zurn elkay water solutions corporation bullish and bearish analyst opinions

This section ties “Zurn elkay water solutions corporation bullish and bearish analyst opinions” to Zurn Elkay Water Solutions Corp (ticker ZWS), SEC Central Index Key 1439288, an EDGAR registrant classified as “General Industrial Machinery & Equipment” and organised in DE, formerly known as Zurn Water Solutions Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-16. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-09 by Zurn Elkay Water Solutions Corp (CIK 1439288) — source document:

Zurn Elkay Water Solutions Corporation ("Zurn Elkay", "we", "us", "our", or the "Company") is a growth-oriented, pure-play water management business that designs, procures, manufactures, and markets what we believe to be the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. Our product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products, and filtered drinking water products for public and private spaces that deliver superior value to building owners, positively impact the environment and human hygiene and reduce product installation time. Our heritage of innovation and specification has allowed us to provide highly-engineered, mission-critical solutions to customers for decades and affords us the privilege of having long-term, valued relationships with market leaders.

Financial trend for Zurn Elkay Water Solutions Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.28 billion (2022-12-31) to $1.53 billion (2023-12-31), a change of +19.4%; net income (loss) went from $61.70 million (2022-12-31) to $198.00 million (2025-12-31), a change of +220.9%; total assets went from $2.86 billion (2022-12-31) to $2.68 billion (2025-12-31), a change of -6.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1439288, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Zurn Elkay Water Solutions Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Zurn Elkay Water Solutions Corp (CIK 1439288) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-28, and the most recent 10-K annual report was filed 2026-02-09. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 88 8-K or 6-K reports in Zurn Elkay Water Solutions Corp’s recent EDGAR index, the 4 listed here run from 2026-05-01 to 2026-07-28, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1439288 is on the EDGAR company page; the latest 10-K there is dated 2026-02-09 and the oldest filing in the recent index dates from 2017-03-09. Insider trades for Zurn Elkay Water Solutions Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Acuity rm group plc ord bullish and bearish analyst opinions

“plc” is the UK public limited company form, so the company’s accounts are filed at Companies House. The name “Acuity rm group plc ord” therefore points to a company organised in the United Kingdom, and its official disclosures are on Companies House and the London Stock Exchange RNS announcements (find-and-update.company-information.service.gov.uk), not on EDGAR.

No SEC filer could be matched to “Acuity rm group plc ord bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Acuity rm group plc ord”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “acuity” (search terms considered: acuity, ord).

Even the shorter phrase “Acuity rm group” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (acuity, ord) point to a business outside the SEC system or one known by another legal name.

The wording suggests a business based in the United Kingdom. Companies there file with the London Stock Exchange and the FCA National Storage Mechanism rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “acuity” is therefore the the United Kingdom regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 39 entities whose registered name contains the word “acuity”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “acuity” 39, “ord” 8. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “acuity” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Aim immunotech inc. bullish and bearish analyst opinions

This section ties “Aim immunotech inc. bullish and bearish analyst opinions” to AIM ImmunoTech Inc. (ticker AIM), SEC Central Index Key 946644, an EDGAR registrant classified as “Biological Products, (No Diagnostic Substances)” and organised in DE, formerly known as AIM ImmunoTech Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-23. Nothing here is a recommendation to trade the security.

Financial trend for AIM ImmunoTech Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $141,000 (2022-12-31) to $88,000 (2025-12-31), a change of -37.6%; net income (loss) went from -$19.45 million (2022-12-31) to -$13.96 million (2025-12-31), a change of +28.2%; total assets went from $40.49 million (2022-12-31) to $5.78 million (2025-12-31), a change of -85.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 946644, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures AIM ImmunoTech Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AIM ImmunoTech Inc. (CIK 946644) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-10, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 221 8-K or 6-K reports in AIM ImmunoTech Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-11 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1000 recent EDGAR filings, AIM ImmunoTech Inc. most often filed 4 (375), 8-K (221), DEFA14A (40), 10-Q (39). A selection from 2026-09-17 to 2026-10-23:

The full record for CIK 946644 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2013-11-08. Insider trades for AIM ImmunoTech Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Alvo minerals limited bullish and bearish analyst opinions

Read from its name, “Alvo minerals limited” is a a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada) entity — “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. Its accounts and exchange notices are published through that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Alvo minerals limited bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Alvo minerals limited”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “alvo” (search terms considered: alvo, minerals).

EDGAR’s company index has 1 entities whose registered name contains the word “alvo”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “alvo” 1, “minerals” 475. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “alvo”: ALVO JACK (CIK 1557707); containing “minerals”: 1789 MINERALS FUND I, LP (CIK 1791248), AAA MINERALS INC. (CIK 1304741), AB MINERALS INVESTMENT CLUB, LLC (CIK 1562460). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “alvo” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Aprea therapeutics, inc. bullish and bearish analyst opinions

This section ties “Aprea therapeutics, inc. bullish and bearish analyst opinions” to Aprea Therapeutics, Inc. (ticker APRE), SEC Central Index Key 1781983, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-08-28. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-16 by Aprea Therapeutics, Inc. (CIK 1781983) — source document:

We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects. Specifically, we develop small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. We have assembled a team with extensive experience in the discovery, development, and commercialization of oncology drugs to support our mission of developing novel synthetic lethality-based cancer therapeutics. Aprea Therapeutics AB was originally incorporated in 2002 and commenced principal operations in 2006.

Financial trend for Aprea Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$112.66 million (2022-12-31) to -$12.60 million (2025-12-31), a change of +88.8%; total assets went from $30.16 million (2022-12-31) to $15.93 million (2025-12-31), a change of -47.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1781983, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Aprea Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Aprea Therapeutics, Inc. (CIK 1781983) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-12, and the most recent 10-K annual report was filed 2026-03-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 93 8-K or 6-K reports in Aprea Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-17 to 2026-08-28, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1781983 is on the EDGAR company page; the latest 10-K there is dated 2026-03-16 and the oldest filing in the recent index dates from 2019-07-12. Insider trades for Aprea Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Asix electronics corporation bullish and bearish analyst opinions

What this search refers to. ASIX Electronics Corporation is a Taiwanese fabless chip company (Ethernet and USB controllers) listed in Taiwan, reporting through MOPS. Official source: mops.twse.com.tw.

No SEC filer could be matched to “Asix electronics corporation bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Asix electronics corporation” appears in 7 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “asix” (search terms considered: asix, electronics, corporation).

In the 7 most relevant full-text hits returned for “Asix electronics corporation”, filings range from 2022-10-28 to 2024-04-26. The filers whose documents mention it most often are John Hancock Funds II (CIK 0001331971) (7 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 0 entities whose registered name contains the word “asix”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “asix” 0, “electronics” 250, “corporation” 486. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “electronics”: ACCUSPEC ELECTRONICS LLC (CIK 1357186), ACI ELECTRONICS LLC (CIK 1403015), ADVANCED OPTICS ELECTRONICS INC (CIK 1020657); containing “corporation”: 1787 FINANCIAL CORPORATION, INC. (CIK 1706256), A.BRIDGE REALVEST SECURITIES CORPORATION (CIK 1005399), ABACUS SECURITIES CORPORATION (CIK 783252). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “asix” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Axo metals corp. bullish and bearish analyst opinions

What this search refers to. Axo Metals Corp. is a Canadian-style junior mining name; Canadian exploration companies file technical reports and financials on SEDAR+. Official source: www.sedarplus.ca.

No SEC filer could be matched to “Axo metals corp. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Axo metals corp.” appears in 8 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “axo” (search terms considered: axo, metals).

In the 8 most relevant full-text hits returned for “Axo metals corp.”, filings range from 2026-08-05 to 2026-09-25. The filers whose documents mention it most often are Franklin Gold & Precious Metals Fund (CIK 0000083293) (3 hits); OR Royalties Inc. (OR) (CIK 0001627272) (3 hits); FRANKLIN TEMPLETON VARIABLE INSURANCE PRODUCTS TRUST (CIK 0000837274) (2 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 0 entities whose registered name contains the word “axo”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “axo” 0, “metals” 474. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “metals”: A-MARK PRECIOUS METALS, INC. (CIK 1591588), ABERDEEN STANDARD PRECIOUS METALS BASKET ETF TRUST (CIK 1483386), ABITIBI METALS CORP. (CIK 2133215). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “axo” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Berto acquisition corp. bullish and bearish analyst opinions

This section ties “Berto acquisition corp. bullish and bearish analyst opinions” to Berto Acquisition Corp. (ticker TACO, TACOU, TACOW), SEC Central Index Key 2033122, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-31 by Berto Acquisition Corp. (CIK 2033122) — source document:

We are a blank check company incorporated on July 15, 2024 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We have neither engaged in any operations nor generated any revenue to date. Based on our business activities, the Company is a “shell company” as defined under the Exchange Act of 1934 (the “Exchange Act”) because we have no operations and nominal assets consisting almost entirely of cash. On November 11, 2024, our Sponsor and its affiliates purchased $23,957 for an aggregate of 6,887,500 ordinary shares and a consultant, Meteora Capital, LLC (“Meteora”), paid $1,043 for an aggregate of 300,000 ordinary shares (such shares, the “founder shares”).

Financial trend for Berto Acquisition Corp. from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) was tagged only for 2025-12-31 at $7.88 million; total assets went from $434,044 (2024-12-31) to $309.39 million (2025-12-31), a change of +71181.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2033122, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Berto Acquisition Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Berto Acquisition Corp. (CIK 2033122) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Berto Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 8 such filings (424B4, 425, S-1, S-1/A, S-1MEF) appear in its recent index, the newest dated 2025-10-29.

Current reports. Of the 5 8-K or 6-K reports in Berto Acquisition Corp.’s recent EDGAR index, the 4 listed here run from 2025-05-07 to 2025-10-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2033122 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2025-02-10. Insider trades for Berto Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Boqii holding limited bullish and bearish analyst opinions

This section ties “Boqii holding limited bullish and bearish analyst opinions” to Boqii Holding Ltd (ticker BQ), SEC Central Index Key 1815021, an EDGAR registrant classified as “Retail-Retail Stores, NEC” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-08-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-07-13 by Boqii Holding Ltd (CIK 1815021) — source document:

In November 2012, Shanghai Guangcheng was established in the PRC. In November 2012 and March 2013, Guangcheng Information and Shanghai Guangcheng entered into an asset transfer agreement and a supplemental agreement thereto, respectively, pursuant to which Guangcheng Information transferred all of its business operations and assets to Shanghai Guangcheng. We incorporated Boqii, an exempted company with limited liability, in the Cayman Islands, as our offshore holding company in June 2012 to facilitate offshore financing and our initial public offering. In July 2012 and August 2016, Boqii Corporation Limited and Boqii International Limited, two of our wholly owned subsidiaries, were incorporated in Hong Kong. In October 2019, Yoken International Limited (“Yoken International”), our wholly owned subsidiary, was incorporated in Hong Kong.

Financial trend for Boqii Holding Ltd from annual reports, periods 2023-03-31 to 2026-03-31: revenue went from 1,092,094,000 CNY (2023-03-31) to 420,467,000 CNY (2026-03-31), a change of -61.5%; net income (loss) went from -102,799,000 CNY (2023-03-31) to -5,078,000 CNY (2026-03-31), a change of +95.1%; total assets went from 540,800,000 CNY (2023-03-31) to 241,767,000 CNY (2026-03-31), a change of -55.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1815021, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Boqii Holding Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Boqii Holding Ltd (CIK 1815021) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-07-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 69 8-K or 6-K reports in Boqii Holding Ltd’s recent EDGAR index, the 4 listed here run from 2026-05-12 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1815021 is on the EDGAR company page; the latest 20-F there is dated 2026-07-13 and the oldest filing in the recent index dates from 2020-06-22. Insider trades for Boqii Holding Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Brandywine realty trust bdn latest news october 2026

This section ties “Brandywine realty trust bdn latest news october 2026” to BRANDYWINE REALTY TRUST (ticker BDN), SEC Central Index Key 790816, an EDGAR registrant classified as “Real Estate Investment Trusts” and organised in MD. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-22. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-23 by BRANDYWINE REALTY TRUST (CIK 790816) — source document:

We are a self-administered and self-managed real estate investment trust (“REIT”) engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential and mixed-use properties. During the twelve months ended December 31, 2025, we owned and managed properties within four segments: (1) Philadelphia Central Business District (“Philadelphia CBD”), (2) Pennsylvania Suburbs, (3) Austin, Texas, and (4) Other. The Philadelphia CBD segment includes properties located in the City of Philadelphia, Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Other segment includes properties in Washington, D.C., Northern Virginia, Southern Maryland, Camden County, New Jersey and New Castle County, Delaware.

Financial trend for BRANDYWINE REALTY TRUST from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $506.10 million (2022-12-31) to $484.45 million (2025-12-31), a change of -4.3%; net income (loss) went from $53.82 million (2022-12-31) to -$178.25 million (2025-12-31), a change of -431.2%; total assets went from $3.87 billion (2022-12-31) to $3.59 billion (2025-12-31), a change of -7.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 790816, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BRANDYWINE REALTY TRUST did not tag for that period.

For the latest news, the fastest official source is the filing feed: BRANDYWINE REALTY TRUST (CIK 790816) filed 170 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-22, and its overall latest filing is a 8-K dated 2026-10-22. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 170 8-K or 6-K reports in BRANDYWINE REALTY TRUST’s recent EDGAR index, the 4 listed here run from 2026-09-03 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 790816 is on the EDGAR company page; the latest 10-K there is dated 2026-02-23 and the oldest filing in the recent index dates from 2011-08-26. Insider trades for BRANDYWINE REALTY TRUST appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cellyan biotechnology co., ltd bullish and bearish analyst opinions

This section ties “Cellyan biotechnology co., ltd bullish and bearish analyst opinions” to Cellyan Biotechnology Co., Ltd (ticker HKPD), SEC Central Index Key 2007702, an EDGAR registrant classified as “Wholesale-Drugs, Proprietaries & Druggists' Sundries” and organised in Cayman Islands, formerly known as Hong Kong Pharma Digital Technology Holdings Ltd. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-21. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-08-07 by Cellyan Biotechnology Co., Ltd (CIK 2007702) — source document:

Operating and Financial Review and Prospects 53-54 5.A. Operating Results 54-57 5.B. Liquidity and Capital Resources 57-59 5.C. Research and Development, Patents and Licenses, etc. 59 5.D. Trend Information 59 5.E. Critical Accounting Estimates 60-62 Item 6. Directors, Senior Management and Employees 63 6.A. Directors and Senior Management 63-65 6.B. Compensation 65 6.C. Board Practices 66-69 6.D. Employees 69 6.E. Share Ownership 69 6.F. Disclosure of a registrant’s action to recover erroneously awarded compensation 69 Item 7. Major Shareholders and Related Party Transactions 70 7.A. Major Shareholders 70 7.B. Related Party Transactions 71 7.C. Interests of Experts and Counsel 71 Item 8. Financial Information 71 8.A. Consolidated Statements and Other Financial Information 71 8.B. Significant Changes 72 Item 9.

Financial trend for Cellyan Biotechnology Co., Ltd from annual reports, periods 2023-03-31 to 2025-03-31: revenue went from $12.56 million (2023-03-31) to $20.31 million (2025-03-31), a change of +61.8%; net income (loss) went from $998,196 (2023-03-31) to -$27,056 (2025-03-31), a change of -102.7%; total assets went from $8.67 million (2024-03-31) to $9.42 million (2025-03-31), a change of +8.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2007702, tags Assets, ProfitLoss, Revenue; 3 periods shown, dashes mark figures Cellyan Biotechnology Co., Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Cellyan Biotechnology Co., Ltd (CIK 2007702) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-08-07. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 16 8-K or 6-K reports in Cellyan Biotechnology Co., Ltd’s recent EDGAR index, the 4 listed here run from 2026-09-10 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2007702 is on the EDGAR company page; the latest 20-F there is dated 2026-08-07 and the oldest filing in the recent index dates from 2024-03-29. Insider trades for Cellyan Biotechnology Co., Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Chemung financial corporation bullish and bearish analyst opinions

This section ties “Chemung financial corporation bullish and bearish analyst opinions” to CHEMUNG FINANCIAL CORP (ticker CHMG), SEC Central Index Key 763563, an EDGAR registrant classified as “State Commercial Banks” and organised in NY. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-22. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-13 by CHEMUNG FINANCIAL CORP (CIK 763563) — source document:

The Corporation was incorporated on January 2, 1985 under the laws of the State of New York and is headquartered in Elmira, New York. The Corporation was organized for the purpose of acquiring the Bank. The Bank was established in 1833 under the name Chemung Canal Bank, and was subsequently granted a New York State bank charter in 1895. In 1902, the Bank was reorganized as a New York State trust company under the name Elmira Trust Company, and its name was changed to Chemung Canal Trust Company in 1903. The Corporation became a financial holding company in June 2000. Financial holding company status provided the Corporation with the flexibility to offer an array of financial services, such as insurance products, mutual funds, and brokerage services, which provide additional sources of fee-based income and allows the Corporation to better serve its customers.

Financial trend for CHEMUNG FINANCIAL CORP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $81.47 million (2022-12-31) to $132.84 million (2025-12-31), a change of +63.0%; net income (loss) went from $28.78 million (2022-12-31) to $15.10 million (2025-12-31), a change of -47.5%; total assets went from $2.65 billion (2022-12-31) to $2.71 billion (2025-12-31), a change of +2.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 763563, tags Assets, InterestAndDividendIncomeOperating, NetIncomeLoss; 4 periods shown, dashes mark figures CHEMUNG FINANCIAL CORP did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on CHEMUNG FINANCIAL CORP (CIK 763563) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-10-22, and the most recent 10-K annual report was filed 2026-03-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

For reported results, CHEMUNG FINANCIAL CORP’s (CIK 763563) latest 10-Q is dated 2026-08-06 and its latest annual report (10-K) 2026-03-13. Earnings releases appear as 8-K Item 2.02 filings; 49 are in the recent index, the newest on 2026-10-22.

Current reports. Of the 197 8-K or 6-K reports in CHEMUNG FINANCIAL CORP’s recent EDGAR index, the 4 listed here run from 2026-07-27 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 763563 is on the EDGAR company page; the latest 10-K there is dated 2026-03-13 and the oldest filing in the recent index dates from 2015-01-08. Insider trades for CHEMUNG FINANCIAL CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Conexeu sciences inc. bullish and bearish analyst opinions

This section ties “Conexeu sciences inc. bullish and bearish analyst opinions” to Conexeu Sciences Inc. (ticker CNXU), SEC Central Index Key 2066836, an EDGAR registrant classified as “Orthopedic, Prosthetic & Surgical Appliances & Supplies” and organised in NV. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a D dated 2026-10-21. Nothing here is a recommendation to trade the security.

Financial trend for Conexeu Sciences Inc. from quarterly and annual reports (three-month periods), periods 2025-07-31 to 2026-07-31: net income (loss) went from -$1.30 million (2025-07-31) to -$7.73 million (2026-07-31), a change of -494.9%; total assets went from $8.20 million (2026-04-30) to $7.16 million (2026-07-31), a change of -12.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2066836, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Conexeu Sciences Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Conexeu Sciences Inc. (CIK 2066836) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 5 8-K or 6-K reports in Conexeu Sciences Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-09 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 86 recent EDGAR filings, Conexeu Sciences Inc. most often filed D (18), 3 (15), 4 (11), SCHEDULE 13G (7). A selection from 2026-09-28 to 2026-10-21:

The full record for CIK 2066836 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-05-09. Insider trades for Conexeu Sciences Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Curanex pharmaceuticals inc common stock bullish and bearish analyst opinions

This section ties “Curanex pharmaceuticals inc common stock bullish and bearish analyst opinions” to Curanex Pharmaceuticals Inc (ticker CURX), SEC Central Index Key 2025942, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in NV. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a S-8 dated 2026-10-19. Nothing here is a recommendation to trade the security.

Financial trend for Curanex Pharmaceuticals Inc from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) went from -$361,506 (2024-12-31) to -$4.23 million (2025-12-31), a change of -1068.8%; total assets went from $517,935 (2024-12-31) to $11.58 million (2025-12-31), a change of +2135.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2025942, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Curanex Pharmaceuticals Inc did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Curanex Pharmaceuticals Inc (CIK 2025942) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 13 8-K or 6-K reports in Curanex Pharmaceuticals Inc’s recent EDGAR index, the 4 listed here run from 2026-05-14 to 2026-10-19, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 65 recent EDGAR filings, Curanex Pharmaceuticals Inc most often filed 8-K (13), 3 (9), CORRESP (8), S-1/A (6). A selection from 2026-06-18 to 2026-10-19:

The full record for CIK 2025942 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2024-06-20. Insider trades for Curanex Pharmaceuticals Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cytomed therapeutics limited bullish and bearish analyst opinions

This section ties “Cytomed therapeutics limited bullish and bearish analyst opinions” to CytoMed Therapeutics Ltd (ticker GDTC), SEC Central Index Key 1873093, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Singapore, formerly known as CytoMed Therapeutics Pte. Ltd. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G/A dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-03-31 by CytoMed Therapeutics Ltd (CIK 1873093) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 115 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 123 A. DIRECTORS AND SENIOR MANAGEMENT 123 B. COMPENSATION 128 C. BOARD PRACTICES 130 D. EMPLOYEES 131 E. SHARE OWNERSHIP 133 F. DISCLOSURE OF A REGISTRANT’S ACTION TO RECOVER ERRONEOUSLY AWARDED COMPENSATION. 133 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 133 A. MAJOR SHAREHOLDERS 133 B. RELATED PARTY TRANSACTIONS 134 C. INTERESTS OF EXPERTS AND COUNSEL 135 ITEM 8. FINANCIAL INFORMATION 135 ITEM 9. THE OFFER AND LISTING 135 A. OFFERING AND LISTING DETAILS 135 B. PLAN OF DISTRIBUTION 135 C. MARKETS 135 D. DILUTION 135 E. EXPENSE OF THE ISSUE 135 ITEM 10. ADDITIONAL INFORMATION 136 A. SHARE CAPITAL 136 B. CONSTITUTION OF THE COMPANY 136 C. MATERIAL CONTRACTS 136 D. EXCHANGE CONTROLS 136 E. TAXATION 136 F. DIVIDENDS AND PAYING AGENTS 144 G. STATEMENT BY EXPERTS 144 H. DOCUMENTS ON DISPLAY 144 I. SUBSIDIARY INFORMATION 144 J. ANNUAL REPORT TO SECURITY HOLDERS 144 ITEM 11.

Financial trend for CytoMed Therapeutics Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 69,501 SGD (2024-12-31) to 324,387 SGD (2025-12-31), a change of +366.7%; net income (loss) went from -3,131,452 SGD (2022-12-31) to -3,996,336 SGD (2025-12-31), a change of -27.6%; total assets went from 5,227,058 SGD (2022-12-31) to 7,984,953 SGD (2025-12-31), a change of +52.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1873093, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures CytoMed Therapeutics Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on CytoMed Therapeutics Ltd (CIK 1873093) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 41 8-K or 6-K reports in CytoMed Therapeutics Ltd’s recent EDGAR index, the 4 listed here run from 2026-06-03 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1873093 is on the EDGAR company page; the latest 20-F there is dated 2026-03-31 and the oldest filing in the recent index dates from 2021-09-28. Insider trades for CytoMed Therapeutics Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Dhc software co.,ltd. bullish and bearish analyst opinions

Read from its name, “Dhc software co.,ltd.” is a China, Taiwan, Korea or Japan entity — “Co., Ltd.” is the English rendering used by limited companies across East Asia. Its accounts and exchange notices are published through the home-exchange disclosure system (SSE/SZSE in mainland China, MOPS in Taiwan, DART in Korea, EDINET in Japan) (mops.twse.com.tw); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Dhc software co.,ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Dhc software co.,ltd.” appears in 8903+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “dhc” (search terms considered: dhc, software).

A broader EDGAR full-text search for the shorter phrase “Dhc software co.” finds 8921+ filing documents; among the top 100, the filers mentioning it most are Invesco Exchange-Traded Fund Trust II (CIK 0001378872) (28); Global X Funds (CIK 0001432353) (17); iSHARES TRUST (CIK 0001100663) (15). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 100 most relevant full-text hits returned for “Dhc software co.,ltd.”, filings range from 2015-11-27 to 2026-09-29. The filers whose documents mention it most often are Invesco Exchange-Traded Fund Trust II (CIK 0001378872) (28 hits); Global X Funds (CIK 0001432353) (17 hits); iSHARES TRUST (CIK 0001100663) (15 hits); Krane Shares Trust (CIK 0001547576) (15 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 22 entities whose registered name contains the word “dhc”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “dhc” 22, “software” 485. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “dhc” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Enveric biosciences, inc. bullish and bearish analyst opinions

This section ties “Enveric biosciences, inc. bullish and bearish analyst opinions” to Enveric Biosciences, Inc. (ticker ENVB), SEC Central Index Key 890821, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE, formerly known as AMERI Holdings, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-14. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-27 by Enveric Biosciences, Inc. (CIK 890821) — source document:

Company Information We were incorporated under the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell company immediately prior to the completion of a “reverse merger” transaction on May 26, 2015, whereby Ameri100 Acquisition, Inc., a Delaware corporation and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners Inc. (“Ameri and Partners”), a Delaware corporation (the “2015 Merger”). In connection with the 2015 Merger, we changed our name to AMERI Holdings, Inc. The Ameri business ceased to be part of the Company on December 30, 2020, pursuant to a spin-off transaction. The Amalgamation was completed on September 16, 2021.

Financial trend for Enveric Biosciences, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$18.47 million (2022-12-31) to -$8.77 million (2025-12-31), a change of +52.5%; total assets went from $19.55 million (2022-12-31) to $5.10 million (2025-12-31), a change of -73.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 890821, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Enveric Biosciences, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Enveric Biosciences, Inc. (CIK 890821) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 260 8-K or 6-K reports in Enveric Biosciences, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-29 to 2026-08-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 890821 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2001-05-11. Insider trades for Enveric Biosciences, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Evolution powerx corp. bullish and bearish analyst opinions

What this search refers to. Evolution PowerX Corp. is a corporate name without an EDGAR registration; if it is a Canadian-listed issuer, SEDAR+ holds its continuous-disclosure documents. Official source: www.sedarplus.ca.

No SEC filer could be matched to “Evolution powerx corp. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Evolution powerx corp.” appears in 2 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “evolution” (search terms considered: evolution, powerx).

In the 2 most relevant full-text hits returned for “Evolution powerx corp.”, filings range from 2026-08-19 to 2026-08-19. The filers whose documents mention it most often are Dimensional ETF Trust (CIK 0001816125) (1 hit); DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (1 hit). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 193+ entities whose registered name contains the word “evolution”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “evolution” 229, “powerx” 1. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “evolution” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Farmmi, inc. bullish and bearish analyst opinions

This section ties “Farmmi, inc. bullish and bearish analyst opinions” to Farmmi, Inc. (ticker FAMI), SEC Central Index Key 1701261, an EDGAR registrant classified as “Canned, Fruits, Veg, Preserves, Jams & Jellies” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-08-27, and this view starts from filings dated on or before 2026-05-06. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-02-10 by Farmmi, Inc. (CIK 1701261) (passage 2, continuing from the earlier excerpt) — source document:

Yefang Zhang and Mr. Zhengyu Wang. Forasen Group (initially named as Lishui Forasen Green Industry Group) was established in April 2003. Forasen Group’s primary business areas used to include rubber trading, mushroom sales, biomass power generation, and marketing. Mr. Wang and Ms. Zhang decided to spin off various business sectors from Forasen Group and to develop them separately. Since 2010, they began to spin off bamboo-based charcoal businesses by establishing several offshore and domestic companies and re-organizing related operating entities in China. In 2011, they established Tantech Holdings Ltd, which completed an IPO and listing on the Nasdaq Capital Market in March 2015. Since 2015, Ms. Zhang and Mr. Wang started to spin off the edible fungi business from Forasen Group by establishing several offshore companies and re-organizing related operating entities in China.

Financial trend for Farmmi, Inc. from annual reports, periods 2018-09-30 to 2021-09-30: revenue went from $28.36 million (2019-09-30) to $39.29 million (2021-09-30), a change of +38.5%; net income (loss) went from $3.22 million (2018-09-30) to $2.36 million (2021-09-30), a change of -26.9%; total assets went from $22.08 million (2018-09-30) to $165.69 million (2021-09-30), a change of +650.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1701261, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Farmmi, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Farmmi, Inc. (CIK 1701261) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-02-10. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 106 8-K or 6-K reports in Farmmi, Inc.’s recent EDGAR index, the 4 listed here run from 2026-02-25 to 2026-05-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1701261 is on the EDGAR company page; the latest 20-F there is dated 2026-02-10 and the oldest filing in the recent index dates from 2017-05-05. One example from this record is the SCHEDULE 13G filed 2026-07-06 (document). Insider trades for Farmmi, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Figx capital acquisition corp. analyst opinions and stock outlook

This section ties “Figx capital acquisition corp. analyst opinions and stock outlook” to FIGX Capital Acquisition Corp. (ticker FIGX, FIGXU, FIGXW), SEC Central Index Key 2059033, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-08-14, and this view starts from filings dated on or before 2025-06-25. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-09 by FIGX Capital Acquisition Corp. (CIK 2059033) (passage 4, continuing from the earlier excerpt) — source document:

A total of $150,650,000, comprised of the proceeds from the Initial Public Offering and the Private Placement, was placed in the Trust Account maintained by Continental, acting as trustee. We must complete our initial Business Combination by (i) June 30, 2027, the end of our Combination Period, which is 24 months from the closing of our Initial Public Offering, (ii) such earlier liquidation date as our Board may approve or (iii) such later date as our shareholders may approve pursuant to the Amended and Restated Articles. If our initial Business Combination is not consummated by the end of our Combination Period, our existence will terminate, and we will distribute all amounts in the Trust Account as described elsewhere in this Report.

Analyst ratings, price targets and “bullish” or “bearish” calls on FIGX Capital Acquisition Corp. (CIK 2059033) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-09. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Other filings. Across its 40 recent EDGAR filings, FIGX Capital Acquisition Corp. most often filed 3 (7), 10-Q (5), SCHEDULE 13G (4), 8-K (4). A selection from 2025-06-26 to 2025-06-30:

The full record for CIK 2059033 is on the EDGAR company page; the latest 10-K there is dated 2026-03-09 and the oldest filing in the recent index dates from 2025-04-01. One example from this record is the 8-K filed 2025-08-13 (document). Insider trades for FIGX Capital Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Fortress blue owl apollo ares blackstone starwood hps golub news

Alternative-asset managers and private-credit lenders searched together; HPS and Fortress are not stand-alone SEC-reporting public companies, so they are not tabled. What follows is each company’s own disclosure trail as EDGAR showed it on Oct 25, 2026.

Blackstone Inc. (BX; investment advice, incorporated in DE): its index shows the 8-K of 2026-10-22 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-10-15 covering 5.02 (departure/election of directors or officers). Year to 2025-12-31: reported revenue $14.45 billion, bottom line $3.02 billion (10-K, 2026-02-27).

BLUE OWL CAPITAL INC. (OWL; investment advice, incorporated in NJ) filed the 8-K of 2026-10-15 covering 1.01 (entry into a material definitive agreement), 2.03 (creation of a direct financial obligation), 9.01 (financial statements and exhibits); the 8-K of 2026-08-18 covering 1.01 (entry into a material definitive agreement), 2.03 (creation of a direct financial obligation), 8.01 (other events), 9.01 (financial statements and exhibits). Year to 2025-12-31: FY revenue tagged at $567.75 million, profit or loss $78.83 million (10-K, 2026-02-19).

STARWOOD PROPERTY TRUST, INC. (STWD; real estate investment trusts) — recent current reports: the 8-K of 2026-08-13 covering 5.02 (departure/election of directors or officers); the 8-K of 2026-08-06 covering 2.02 (results of operations and financial condition). Year to 2025-12-31: revenue of $1.84 billion, net income (loss) $411.54 million (10-K, 2026-02-25).

Apollo Global Management, Inc. (APO; investment advice, incorporated in DE) filed the 8-K of 2026-10-20 covering 5.02 (departure/election of directors or officers), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits); the 8-K of 2026-10-05 covering 2.02 (results of operations and financial condition), 7.01 (regulation fd disclosure). Year to 2025-12-31: FY revenue tagged at $32.05 billion, profit or loss $3.49 billion (10-K, 2026-02-25).

GOLUB CAPITAL BDC, Inc. (GBDC; —, incorporated in DE) filed the 8-K of 2026-10-06 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits); the 8-K of 2026-08-11 covering 8.01 (other events). Its latest annual report is the 10-K filed 2025-11-18.

Ares Management Corp (ARES; investment advice, incorporated in DE) — recent current reports: the 8-K of 2026-09-30 covering 7.01 (regulation fd disclosure); the 8-K of 2026-07-31 covering 2.02 (results of operations and financial condition), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits). Year to 2025-12-31: revenue of $4.76 billion, net income (loss) $527.36 million (10-K, 2026-02-25).

Item 2.02 — results of operations and financial condition — the item that accompanies an earnings release — appears this many times per company: BX 38 (latest 2026-10-22), OWL 22 (latest 2026-07-30), STWD 72 (latest 2026-08-06), APO 29 (latest 2026-10-05), GBDC 215 (latest 2026-10-06), ARES 36 (latest 2026-07-31).

Updated Oct 25, 2026 ET

Greenwich lifesciences glsi-100 news

This section ties “Greenwich lifesciences glsi-100 news” to Greenwich LifeSciences, Inc. (ticker GLSI), SEC Central Index Key 1799788, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-11, and this view starts from filings dated on or before 2025-11-03. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-06-01 by Greenwich LifeSciences, Inc. (CIK 1799788) (passage 3, continuing from the earlier excerpt) — source document:

GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. GM-CSF is available in lyophilized form exclusively from one manufacturer. We will continue to be dependent on the manufacturer for our supply of GM-CSF in our ongoing GP2 clinical trials and upon potential commercialization of GP2. Although GM-CSF is only approved for sale in the U.S. by the FDA and is available in other countries on a named patient basis through a specialized company that focuses on making products approved in the U.S. available globally, GM-CSF may be registered for sale in other countries by the manufacturer in the future. Cancer Immunotherapy Cancer immunotherapy is a new method of cancer treatment among more established treatment options such as surgery, chemotherapy, targeted therapy, and radiation therapy.

Financial trend for Greenwich LifeSciences, Inc. from annual reports, periods 2019-12-31 to 2021-12-31: net income (loss) went from -$3.43 million (2019-12-31) to -$4.57 million (2021-12-31), a change of -33.4%; total assets went from $26,671 (2019-12-31) to $27.22 million (2021-12-31), a change of +101946.7%. Values are as filed and not adjusted for restatements, splits or currency.

Current reports. Of the 31 8-K or 6-K reports in Greenwich LifeSciences, Inc.’s recent EDGAR index, the 4 listed here run from 2022-07-12 to 2023-03-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1799788 is on the EDGAR company page; the latest 10-K there is dated 2026-06-01 and the oldest filing in the recent index dates from 2020-01-27. One example from this record is the 4 filed 2026-01-15 (document). Insider trades for Greenwich LifeSciences, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Grosvenor resource corporation bullish and bearish analyst opinions

What this search refers to. Grosvenor Resource Corporation is a Canadian junior resource company name; SEDAR+ is the official repository for Canadian issuers’ filings. Official source: www.sedarplus.ca.

No SEC filer could be matched to “Grosvenor resource corporation bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Grosvenor resource corporation”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “grosvenor” (search terms considered: grosvenor, resource, corporation).

EDGAR’s company index has 181 entities whose registered name contains the word “grosvenor”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “grosvenor” 181, “resource” 479, “corporation” 486. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “grosvenor”: ARCHSTONE GROSVENOR TOWER REIT LP (CIK 1566981), CION GROSVENOR INFRASTRUCTURE FUND (CIK 1997906), CION GROSVENOR INFRASTRUCTURE MASTER FUND, LLC (CIK 2001586); containing “resource”: ABACAN RESOURCE CORP (CIK 1001084), ABRAPLATA RESOURCE CORP. (CIK 1728426), ABRASILVER RESOURCE CORP. (CIK 2059474); containing “corporation”: 1787 FINANCIAL CORPORATION, INC. (CIK 1706256), A.BRIDGE REALVEST SECURITIES CORPORATION (CIK 1005399), ABACUS SECURITIES CORPORATION (CIK 783252). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “grosvenor” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Heartsciences inc. bullish and bearish analyst opinions

This section ties “Heartsciences inc. bullish and bearish analyst opinions” to HeartSciences Inc. (ticker HSCS, HSCSW), SEC Central Index Key 1468492, an EDGAR registrant classified as “Finance Services” and organised in TX, formerly known as Heart Test Laboratories, Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13D/A dated 2026-10-23. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-07-23 by HeartSciences Inc. (CIK 1468492) — source document:

We are a healthcare information technology company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”). Our first commercial product is MyoVista Insights™, a cloud-native, vendor- and device-agnostic ECG management platform designed to modernize ECG workflows and enable scalable deployment of AI-ECG capabilities across healthcare systems. MyoVista Insights™ is classified as a Medical Device Data System (“MDDS”) and is exempt from the FDA 510(k) requirements. The platform is designed to streamline ECG study organization, enhance waveform analysis, and simplify clinical workflows, enabling more efficient interpretation, storage, and management of ECG data. It is also designed to host AI-ECG algorithms from multiple vendors and integrate them directly into clinical workflows, providing a flexible and extensible foundation for the adoption of AI in ECG. Following its early adopter launch in 2025, we have implemented phased enhancements to MyoVista Insights™. In March 2026, we released a significant version upgrade for broader deployment across cardiology and healthcare IT environments.

Financial trend for HeartSciences Inc. from annual reports, periods 2025-04-30 to 2026-06-30: revenue went from $4,350 (2025-04-30) to $4,319 (2026-04-30), a change of -0.7%; net income (loss) went from -$8.77 million (2025-04-30) to -$9.14 million (2026-04-30), a change of -4.3%; total assets went from $4.22 million (2025-04-30) to $5.26 million (2026-06-30), a change of +24.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1468492, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures HeartSciences Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on HeartSciences Inc. (CIK 1468492) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-15, and the most recent 10-K annual report was filed 2026-07-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 93 8-K or 6-K reports in HeartSciences Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-15 to 2026-10-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1468492 is on the EDGAR company page; the latest 10-K there is dated 2026-07-23 and the oldest filing in the recent index dates from 2009-07-30. Insider trades for HeartSciences Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Hemab therapeutics sec filing ceo 2026

The full record for CIK 2114044 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-02-27. One example from this record is the SCHEDULE 13D filed 2026-05-11 (document). Insider trades for Hemab Therapeutics Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

More of the filing record for Hemab Therapeutics Holdings, Inc. (CIK 2114044), filings 2026-04-28 to 2026-04-30: 3 on 2026-04-30; S-1MEF on 2026-04-30; CERT on 2026-04-30; S-1/A on 2026-04-30; S-1/A on 2026-04-28. Each form type has a fixed purpose under SEC rules, so the mix shows what kind of events the company has been reporting.

More of the filing record for Hemab Therapeutics Holdings, Inc. (CIK 2114044), filings 2026-02-27 to 2026-04-27: 8-A12B on 2026-04-27; S-1/A on 2026-04-27; S-1 on 2026-04-10; DRS/A on 2026-04-02; DRS on 2026-02-27. Each form type has a fixed purpose under SEC rules, so the mix shows what kind of events the company has been reporting.

Updated Oct 25, 2026 ET

Hemab therapeutics sec filing ceo october 2026

Other filings. Across its 50 recent EDGAR filings, Hemab Therapeutics Holdings, Inc. most often filed 3 (12), 4 (10), SCHEDULE 13G (8), 8-K (5). A selection from 2026-04-28 to 2026-04-30:

The full record for CIK 2114044 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-02-27. One example from this record is the 4 filed 2026-05-06 (document). Insider trades for Hemab Therapeutics Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Investcorp credit management bdc, inc. bullish and bearish analyst opinions

This section ties “Investcorp credit management bdc, inc. bullish and bearish analyst opinions” to Investcorp Credit Management BDC, Inc. (ticker ICMB), SEC Central Index Key 1578348, an EDGAR registrant classified as “no SIC description” and organised in MD, formerly known as CM Finance Inc. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 10-Q dated 2026-08-14. Nothing here is a recommendation to trade the security.

Financial trend for Investcorp Credit Management BDC, Inc. from annual reports, periods 2023-06-30 to 2025-12-31: net income (loss) went from $3.23 million (2023-06-30) to -$8.85 million (2025-12-31), a change of -373.5%; total assets went from $231.81 million (2023-06-30) to $188.84 million (2025-12-31), a change of -18.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1578348, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Investcorp Credit Management BDC, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Investcorp Credit Management BDC, Inc. (CIK 1578348) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-05-13, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 70 8-K or 6-K reports in Investcorp Credit Management BDC, Inc.’s recent EDGAR index, the 4 listed here run from 2026-04-23 to 2026-06-02, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 453 recent EDGAR filings, Investcorp Credit Management BDC, Inc. most often filed 4 (112), 8-K (70), 10-Q (38), DEFA14A (30). A selection from 2025-11-12 to 2026-08-14:

The full record for CIK 1578348 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2013-07-09. Insider trades for Investcorp Credit Management BDC, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Lexaria bioscience corp. bullish and bearish analyst opinions

This section ties “Lexaria bioscience corp. bullish and bearish analyst opinions” to Lexaria Bioscience Corp. (ticker LEXX), SEC Central Index Key 1348362, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in NV, formerly known as Lexaria Corp. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a EFFECT dated 2026-10-13. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2025-11-28 by Lexaria Bioscience Corp. (CIK 1348362) — source document:

Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECH TM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs (“GLP-1”) and glucose-dependent insulinotropic polypeptide drugs (“GIP”), vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids. Our technology can be applied to a variety of therapeutic indications, including diabetes, weight loss, epilepsy, hypertension and heart disease.

Financial trend for Lexaria Bioscience Corp. from annual reports, periods 2022-08-31 to 2025-08-31: revenue went from $255,397 (2022-08-31) to $705,923 (2025-08-31), a change of +176.4%; net income (loss) went from -$7.27 million (2022-08-31) to -$11.90 million (2025-08-31), a change of -63.7%; total assets went from $7.83 million (2022-08-31) to $4.18 million (2025-08-31), a change of -46.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1348362, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Lexaria Bioscience Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Lexaria Bioscience Corp. (CIK 1348362) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2025-11-28. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 349 8-K or 6-K reports in Lexaria Bioscience Corp.’s recent EDGAR index, the 4 listed here run from 2026-08-10 to 2026-09-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1348362 is on the EDGAR company page; the latest 10-K there is dated 2025-11-28 and the oldest filing in the recent index dates from 2009-08-25. Insider trades for Lexaria Bioscience Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Logprostyle inc. bullish and bearish analyst opinions

This section ties “Logprostyle inc. bullish and bearish analyst opinions” to LOGPROSTYLE INC. (ticker LGPS), SEC Central Index Key 2040290, an EDGAR registrant classified as “Operative Builders” and organised in Japan. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-09-28, and this view starts from filings dated on or before 2026-06-05. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-07-13 by LOGPROSTYLE INC. (CIK 2040290) (passage 2, continuing from the earlier excerpt) — source document:

Soon after LogProstyle’s incorporation, it acquired 100% of the equity interests in LogSuite through share exchanges from the original shareholders of LogSuite. Consequently, the original shareholders of LogSuite each received certain Common Shares proportionally, and LogProstyle, through a restructuring that is accounted for as a reorganization of entities under common control, became the ultimate holding company of LogSuite and LogSuite’s subsidiaries. ● In May 2017, ProstyleRyokan was established by LogProstyle in Kanagawa, Japan. ● In January 2018, we acquired all the equity interest in OkinawaIgeto, and OkinawaIgeto became our wholly-owned subsidiary. ● In August 2020, LogKnot Co., Ltd. was established by LogProstyle in Tokyo, Japan. LogKnot Co., Ltd. was merged into LogSuite due to a reorganization in June 2024 (the “Reorganization”). ● In November 2021, LogKnot Vietnam was established by LogKnot Co., Ltd. in Vietnam.

Financial trend for LOGPROSTYLE INC. from annual reports, periods 2023-03-31 to 2026-03-31: revenue went from 13,264,408,000 JPY (2023-03-31) to 22,221,163,000 JPY (2026-03-31), a change of +67.5%; net income (loss) went from 354,025,000 JPY (2023-03-31) to 759,961,000 JPY (2026-03-31), a change of +114.7%; total assets went from 18,298,284,000 JPY (2023-03-31) to 26,956,895,000 JPY (2026-03-31), a change of +47.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2040290, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures LOGPROSTYLE INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on LOGPROSTYLE INC. (CIK 2040290) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-07-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 23 8-K or 6-K reports in LOGPROSTYLE INC.’s recent EDGAR index, the 4 listed here run from 2026-07-06 to 2026-09-03, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2040290 is on the EDGAR company page; the latest 20-F there is dated 2026-07-13 and the oldest filing in the recent index dates from 2024-10-15. One example from this record is the 6-K filed 2026-09-03 (document). Insider trades for LOGPROSTYLE INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Masterbrand, inc. bullish and bearish analyst opinions

This section ties “Masterbrand, inc. bullish and bearish analyst opinions” to MasterBrand, Inc. (ticker MBC), SEC Central Index Key 1941365, an EDGAR registrant classified as “Wood Household Furniture, (No Upholstered)” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-09-24. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-13 by MasterBrand, Inc. (CIK 1941365) — source document:

MasterBrand, Inc. (“we,” “us,” “our,” “MasterBrand” or the “Company”), was founded over 70 years ago in 1954 under the name United Cabinet Incorp orated. We are the largest manufacturer of residential cabinets in North America, based on 2024 reported net sales. O ur products are sold throughout the United States and Canada to the remodeling and new construction markets through three primary channels: dealers, retailers and builders. On December 14, 2022, our former parent company, Fortune Brands Innovations, Inc. (formerly known as Fortune Brands Home & Security, Inc.) (“Fortune Brands”), completed a tax free spin-off transaction to separate its Cabinets segment into a standalone publicly-traded company (the “Separation”). The Separation was completed through a series of transactions ending with a pro rata distribution of all of the shares of MasterBrand, Inc. common stock owned by Fortune Brands to Fortune Brands shareholders, after which we became an independent, publicly-traded company.

Financial trend for MasterBrand, Inc. from annual reports, periods 2022-12-25 to 2025-12-28: revenue went from $3.28 billion (2022-12-25) to $2.73 billion (2025-12-28), a change of -16.5%; net income (loss) went from $155.40 million (2022-12-25) to $26.70 million (2025-12-28), a change of -82.8%; total assets went from $2.53 billion (2022-12-25) to $3.10 billion (2025-12-28), a change of +22.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1941365, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures MasterBrand, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MasterBrand, Inc. (CIK 1941365) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-04, and the most recent 10-K annual report was filed 2026-02-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 49 8-K or 6-K reports in MasterBrand, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-28 to 2026-09-24, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1941365 is on the EDGAR company page; the latest 10-K there is dated 2026-02-13 and the oldest filing in the recent index dates from 2022-08-17. Insider trades for MasterBrand, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Micropolis ai robotics bullish and bearish analyst opinions

This section ties “Micropolis ai robotics bullish and bearish analyst opinions” to Micropolis AI Robotics (ticker MCRP), SEC Central Index Key 1993431, an EDGAR registrant classified as “Motor Vehicle Parts & Accessories” and organised in Cayman Islands, formerly known as Micropolis Holding Co. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 6-K dated 2026-10-23, and this view starts from filings dated on or before 2025-10-23. Nothing here is a recommendation to trade the security.

Financial trend for Micropolis AI Robotics from annual reports, periods 2022-12-31 to 2024-12-31: revenue went from 577,064 AED (2023-12-31) to 130,043 AED (2024-12-31), a change of -77.5%; net income (loss) went from -11,315,444 AED (2022-12-31) to -22,294,417 AED (2024-12-31), a change of -97.0%; total assets went from 8,637,199 AED (2023-12-31) to 9,841,769 AED (2024-12-31), a change of +13.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1993431, tags Assets, ProfitLoss, Revenue; 3 periods shown, dashes mark figures Micropolis AI Robotics did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Micropolis AI Robotics (CIK 1993431) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2025-05-08. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 17 8-K or 6-K reports in Micropolis AI Robotics’s recent EDGAR index, the 4 listed here run from 2025-06-09 to 2025-10-16, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 71 recent EDGAR filings, Micropolis AI Robotics most often filed 6-K (17), F-1/A (8), CORRESP (8), 3 (7). A selection from 2025-10-14 to 2026-02-27:

The full record for CIK 1993431 is on the EDGAR company page; the latest 20-F there is dated 2025-05-08 and the oldest filing in the recent index dates from 2023-10-13. One example from this record is the 144 filed 2026-04-06 (document). Insider trades for Micropolis AI Robotics appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mobile telecommunications company k.s.c.p. bullish and bearish analyst opinions

“K.S.C.P.” denotes a Kuwaiti public shareholding company. The name “Mobile telecommunications company k.s.c.p.” therefore points to a company organised in Kuwait, and its official disclosures are on Boursa Kuwait disclosures (www.boursakuwait.com.kw), not on EDGAR.

No SEC filer could be matched to “Mobile telecommunications company k.s.c.p. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Mobile telecommunications company k.s.c.p.” appears in 1072+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “telecommunications” (search terms considered: telecommunications).

Even the shorter phrase “telecommunications k.s.c.p.” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (telecommunications) point to a business outside the SEC system or one known by another legal name.

In the 100 most relevant full-text hits returned for “Mobile telecommunications company k.s.c.p.”, filings range from 2019-12-26 to 2026-10-23. The filers whose documents mention it most often are Global X Funds (CIK 0001432353) (16 hits); CAUSEWAY CAPITAL MANAGEMENT TRUST (CIK 0001156906) (15 hits); Dimensional ETF Trust (CIK 0001816125) (11 hits); ADVISORS' INNER CIRCLE FUND (CIK 0000878719) (10 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 180+ entities whose registered name contains the word “telecommunications”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “telecommunications” 185. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “telecommunications” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Mueller water products mwa news october 2026

This section ties “Mueller water products mwa news october 2026” to Mueller Water Products, Inc. (ticker MWA), SEC Central Index Key 1350593, an EDGAR registrant classified as “Miscellaneous Fabricated Metal Products” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 8-K dated 2026-10-22, and this view starts from filings dated on or before 2026-08-26. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2025-11-19 by Mueller Water Products, Inc. (CIK 1350593) (passage 2, continuing from the earlier excerpt) — source document:

Our products and solutions are used by municipalities and the residential and non-residential construction industries. Some of our products have leading positions as a result of their strong brand recognition and reputation for quality, service and innovation. We believe we have one of the largest installed bases of iron gate valves and fire hydrants in the United States. Our iron gate valve and hydrant products are specified for use in the largest 100 metropolitan areas in the United States. Our large installed base, broad product range and well-known brands have led to long-standing relationships with the key distributors and end users of our products. Our consolidated net sales were $1,429.7 million in 2025.

Financial trend for Mueller Water Products, Inc. from quarterly and annual reports (three-month periods), periods 2025-12-31 to 2026-06-30: revenue went from $318.20 million (2025-12-31) to $395.90 million (2026-06-30), a change of +24.4%; net income (loss) went from $43.20 million (2025-12-31) to $67.30 million (2026-06-30), a change of +55.8%; total assets went from $1.85 billion (2025-12-31) to $1.95 billion (2026-06-30), a change of +5.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1350593, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Mueller Water Products, Inc. did not tag for that period.

Current reports. Of the 188 8-K or 6-K reports in Mueller Water Products, Inc.’s recent EDGAR index, the 4 listed here run from 2026-02-12 to 2026-05-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1350593 is on the EDGAR company page; the latest 10-K there is dated 2025-11-19 and the oldest filing in the recent index dates from 2015-01-30. One example from this record is the 4 filed 2026-09-03 (document). Insider trades for Mueller Water Products, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

New century logistics (bvi) limited bullish and bearish analyst opinions

This section ties “New century logistics (bvi) limited bullish and bearish analyst opinions” to New Century Logistics (BVI) Ltd (ticker NCEW), SEC Central Index Key 1968043, an EDGAR registrant classified as “Arrangement of Transportation of Freight & Cargo” and organised in Virgin Islands, British. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-09-04, and this view starts from filings dated on or before 2026-03-31. Nothing here is a recommendation to trade the security.

Business description, quoted from the 20-F filed 2026-02-17 by New Century Logistics (BVI) Ltd (CIK 1968043) (passage 2, continuing from the earlier excerpt) — source document:

As a result, each of NCEW (HK) and Win-Tec became an indirect wholly-owned subsidiary of the Company. NCEW (HK) was incorporated in Hong Kong as a limited liability company on August 15, 2016, with an issued share capital of HK$10,000 divided into 10,000 shares. Though currently inactive, NCEW (HK) was principally engaged in the business of freight forwarding services, and was acquired mainly for handling dangerous goods. Some of the airlines have more stringent requirements on dangerous goods, and will lower the creditability of the freight forwarders if the freight forwarders has previously handled dangerous goods improperly. Win-Tec was incorporated in Hong Kong as a limited liability company on June 28, 2005, with an issued share capital of HK$188,450 with 6 shares.

Analyst ratings, price targets and “bullish” or “bearish” calls on New Century Logistics (BVI) Ltd (CIK 1968043) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-02-17. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 13 8-K or 6-K reports in New Century Logistics (BVI) Ltd’s recent EDGAR index, the 4 listed here run from 2025-07-08 to 2025-09-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1968043 is on the EDGAR company page; the latest 20-F there is dated 2026-02-17 and the oldest filing in the recent index dates from 2023-04-28. One example from this record is the 3 filed 2026-03-31 (document). Insider trades for New Century Logistics (BVI) Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Newamsterdam pharma company n.v. bullish and bearish analyst opinions

This section ties “Newamsterdam pharma company n.v. bullish and bearish analyst opinions” to NewAmsterdam Pharma Co N.V. (ticker NAMS, NAMSW), SEC Central Index Key 1936258, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in Netherlands, formerly known as NewAmsterdam Pharma Co B.V.. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 4 dated 2026-10-02. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-02-18 by NewAmsterdam Pharma Co N.V. (CIK 1936258) — source document:

We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (“LDL-C”) lowering therapy. In multiple Phase 3 trials, we have investigated obicetrapib, an oral, low-dose, once-daily, highly selective cholesteryl ester transfer protein (“CETP”) inhibitor, alone or as a fixed-dose combination (“FDC”) with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of cardiovascular disease (“CVD”) with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Financial trend for NewAmsterdam Pharma Co N.V. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $102.69 million (2022-12-31) to $22.50 million (2025-12-31), a change of -78.1%; net income (loss) went from -$22.63 million (2022-12-31) to -$203.82 million (2025-12-31), a change of -800.5%; total assets went from $478.50 million (2022-12-31) to $769.28 million (2025-12-31), a change of +60.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1936258, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures NewAmsterdam Pharma Co N.V. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on NewAmsterdam Pharma Co N.V. (CIK 1936258) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-02-18. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 75 8-K or 6-K reports in NewAmsterdam Pharma Co N.V.’s recent EDGAR index, the 4 listed here run from 2026-08-05 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1936258 is on the EDGAR company page; the latest 10-K there is dated 2026-02-18 and the oldest filing in the recent index dates from 2022-08-04. Insider trades for NewAmsterdam Pharma Co N.V. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Nextcure, inc. bullish and bearish analyst opinions

This section ties “Nextcure, inc. bullish and bearish analyst opinions” to NextCure, Inc. (ticker NXTC), SEC Central Index Key 1661059, an EDGAR registrant classified as “Pharmaceutical Preparations” and organised in DE. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a SCHEDULE 13G dated 2026-10-20. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-05 by NextCure, Inc. (CIK 1661059) — source document:

An ADC consists of a monoclonal antibody conjugated to a cytotoxic drug via a chemical linker. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Our product candidate SIM0505 is a novel ADC candidate developed by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical, Ltd. or hereinafter “Zaiming”). We obtained (1) an exclusive, worldwide (excluding the Zaiming Territory, as identified below) license to develop, manufacture, and commercialize Zaiming’s clinical-stage ADC candidate, SIM0505, and related compounds (the “Zaiming Products”), and (2) a non-exclusive, worldwide (excluding the Zaiming Territory) license to use Zaiming’s ADC platform technology to develop ADCs based on the Company’s proprietary antibodies for an additional novel target (the “NextCure Products”) (“the License agreement”).

Financial trend for NextCure, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$74.73 million (2022-12-31) to -$55.84 million (2025-12-31), a change of +25.3%; total assets went from $184.16 million (2022-12-31) to $50.18 million (2025-12-31), a change of -72.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1661059, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures NextCure, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on NextCure, Inc. (CIK 1661059) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-05. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 66 8-K or 6-K reports in NextCure, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-14 to 2026-09-25, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1661059 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 2016-01-11. Insider trades for NextCure, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Nmp acquisition corp. bullish and bearish analyst opinions

This section ties “Nmp acquisition corp. bullish and bearish analyst opinions” to NMP Acquisition Corp. (ticker NMP, NMPAR, NMPAU), SEC Central Index Key 2054876, an EDGAR registrant classified as “Blank Checks” and organised in Cayman Islands. The figures and filings below were read from EDGAR on Oct 25, 2026; the most recent filing on record is a 425 dated 2026-09-25. Nothing here is a recommendation to trade the security.

Business description, quoted from the 10-K filed 2026-03-20 by NMP Acquisition Corp. (CIK 2054876) — source document:

We are a blank check exempted company incorporated in the Cayman Islands on December 18, 2024, as a Cayman Islands exempted company with limited liability, formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. We intend to effectuate our initial business combination using cash from the proceeds of our initial public offering and the private placement, our shares, debt or a combination of cash, shares and debt. Our management team is led by our Chief Executive Officer and director, Melanie Figueroa, and our Chief Financial Officer and director, Nadir Ali. Our team consists of experienced professionals and senior operating executives.

Financial trend for NMP Acquisition Corp. from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) was tagged only for 2025-12-31 at $1.78 million; total assets went from $17,800 (2024-12-31) to $117.80 million (2025-12-31), a change of +661685.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2054876, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures NMP Acquisition Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on NMP Acquisition Corp. (CIK 2054876) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-20. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for NMP Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 9 such filings (424B4, 425, S-1, S-1/A) appear in its recent index, the newest dated 2026-09-25.

Current reports. Of the 7 8-K or 6-K reports in NMP Acquisition Corp.’s recent EDGAR index, the 4 listed here run from 2025-08-28 to 2026-09-25, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2054876 is on the EDGAR company page; the latest 10-K there is dated 2026-03-20 and the oldest filing in the recent index dates from 2025-02-10. Insider trades for NMP Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET